Key facts
- Popular weight loss drugs like Ozempic and Wegovy may be linked to an increased risk of hair loss.
- A study analyzed data from nearly 550,000 patients over a 10-year period.
- The research identified an association with telogen effluvium and androgenetic alopecia.
- Regulatory bodies like the FDA and MHRA have received numerous reports of hair loss linked to these medications.
- The FDA is currently evaluating hair loss as a potential safety signal.
New research suggests that popular weight loss drugs, including GLP-1 agonists like Ozempic and Wegovy, may be associated with an increased risk of hair loss. The study, published in the British Medical Journal and involving data from nearly 550,000 patients aged 12 to 89 between 2014 and 2024, found a link to higher rates of alopecia.
Researchers, led by Professor Adam Friedman of GW's dermatology department, identified two types of hair loss potentially affected by these medications: telogen effluvium, a temporary condition often triggered by significant stressors like rapid weight loss, and androgenetic alopecia, a more gradual, genetic form of hair loss. The study found that GLP-1 drugs could accelerate the latter and were associated with a 37% to 68% higher risk of alopecia compared to other diabetes medications.
Co-author Matt Akiska noted that initial clinical trials did not heavily emphasize hair loss as a side effect, and the research was inspired by patient reports. While rapid weight loss is a known trigger for telogen effluvium, the study aimed to examine this more systematically. Akiska emphasized that for most patients, hair loss associated with these drugs is temporary and improves once weight stabilizes.
The study is not intended to discourage the use of these medications, which are recognized for their metabolic and cardiovascular benefits. Instead, researchers advocate for anticipatory counseling, attention to nutrition, and evaluation of reversible factors if hair shedding becomes severe or prolonged. Regulatory bodies like the US FDA and UK's MHRA have received hundreds of reports of hair loss linked to these drugs, with the FDA currently assessing it as a potential safety signal.